Rybelsus vs. Qsymia
See how Rybelsus and Qsymia compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Rybelsus is FDA-approved for blood sugar control and cardiovascular risk reduction in type 2 diabetes, while Qsymia is FDA-approved specifically for chronic weight management.
Rybelsus is a once-daily oral tablet with no abuse potential, while Qsymia is a Schedule IV controlled substance dispensed only through certified REMS pharmacies.
Using Rybelsus for weight loss is off-label, whereas Qsymia carries a labeled indication for that exact purpose.
Rybelsus vs. Qsymia Drug Summary
Rybelsus
Rybelsus is an oral GLP-1 receptor agonist that helps control blood sugar in adults with type 2 diabetes and can lower cardiovascular risk in those with existing heart disease. It contains the same active ingredient as injectable Ozempic but comes as a once-daily tablet taken on an empty stomach. Doctors sometimes prescribe it off-label for weight loss in people without diabetes.
Qsymia
Qsymia combines phentermine, a stimulant that suppresses appetite, with topiramate, an anticonvulsant that helps you feel full, in one once-daily capsule. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in adolescents 12 and older. The dose is increased gradually over about 16 weeks to reach the target maintenance level.
Rybelsus vs. Qsymia Side Effects
Rybelsus
Qsymia
Rybelsus vs. Qsymia Dosage
Rybelsus
Qsymia
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | Days 1-30 |
| Maximum dose | 14 mg once daily | Day 61 onward |
| Dose changes | 2 increases | Every 30 days |
| STAGE | DOSE | WHEN |
| Starting dose | 3.75 mg/23 mg once daily | Days 1-14 |
| Maximum dose | 15 mg/92 mg once daily | Week 17 onward |
| Dose changes | 3 increases | As tolerated |
Rybelsus
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | Days 1-30 |
| Maximum dose | 14 mg once daily | Day 61 onward |
| Dose changes | 2 increases | Every 30 days |
Qsymia
| STAGE | DOSE | WHEN |
| Starting dose | 3.75 mg/23 mg once daily | Days 1-14 |
| Maximum dose | 15 mg/92 mg once daily | Week 17 onward |
| Dose changes | 3 increases | As tolerated |
Rybelsus vs. Qsymia Indications
Rybelsus
Rybelsus is approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in those with existing heart disease. It is not approved for type 1 diabetes or for chronic weight management. Some clinicians prescribe it off-label for weight loss in people without diabetes.
Blood sugar control in type 2 diabetes
Cardiovascular risk reduction in adults with type 2 diabetes and heart disease
Off-label: weight loss in people without diabetes
Not approved for type 1 diabetes or chronic weight management
Qsymia
Qsymia is approved for chronic weight management in adults with obesity or in adults who are overweight with at least one weight-related condition, such as high blood pressure or type 2 diabetes. It is also approved for adolescents 12 and older with obesity. It is not approved for use during pregnancy or breastfeeding.
Chronic weight management in adults with obesity
Chronic weight management in overweight adults with a weight-related condition
Approved for adolescents 12 and older with obesity
Not approved for use in pregnancy or breastfeeding
Rybelsus vs. Qsymia Pros and Cons
Rybelsus
Rybelsus is well studied for blood sugar and cardiovascular outcomes in type 2 diabetes, but using it for weight loss alone is off-label and not FDA-approved. It avoids the abuse potential and REMS restrictions that come with Qsymia, though it carries its own boxed warning for thyroid tumors seen in animal studies.
Pros
Oral tablet, no injection required
FDA-approved for cardiovascular risk reduction in type 2 diabetes
Not a controlled substance
No REMS enrollment or pregnancy testing required
Cons
Not FDA-approved for weight loss; use for that purpose is off-label
Boxed warning for thyroid C-cell tumors seen in rodent studies
Typically costs more without insurance, roughly $998 to $1,029 a month
Must be taken on an empty stomach and wait 30 minutes before eating
Qsymia
Qsymia is FDA-approved specifically for chronic weight management, giving it a labeled indication Rybelsus lacks. As a controlled substance combining a stimulant and an anticonvulsant, it requires REMS enrollment, pregnancy monitoring, and watching for mood or cognitive side effects.
Pros
FDA-approved specifically for chronic weight management
Approved for adolescents 12 and older with obesity
Lower list price, roughly $200 to $350 a month
Non-injectable oral capsule
Cons
Schedule IV controlled substance with abuse potential
Requires REMS enrollment and dispensing through certified pharmacies
Contraindicated in pregnancy; monthly pregnancy testing recommended
Risk of mood changes, cognitive effects, and increased heart rate
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.